Spero Therapeutics (SPRO) AI Stock Analysis

• Market Cap: $129.02M
• Dividend Yield: N/A
• Average Volume (3M): 241.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.69
• Revenue Growth: -67.38%
• EPS Growth: -1076.54%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 56,339,294
• 10 Day Avg. Volume: 331,200
• 30 Day Avg. Volume: 241,300
• PEG Ratio: <0.01
• Price to Book (P/B): 1.21
• Price to Sales (P/S): 1.16
• P/FCF Ratio: -2.37
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: 2.36
• Enterprise Value/Gross Profit: -1.16
• Enterprise Value/Ebitda: -1.87
• 1Y Price Target: $4.00
• Price Target Upside: 74.67% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.64
• Revenue Forecast (FY): $800.00K

• Rating: 48 Neutral
• Price Target: $2.00 ▼(-12.66% Downside)

The score is held back primarily by weak current financial performance (losses and cash burn) and soft technical momentum (below key moving averages with negative MACD). Offsetting factors include a low-debt balance sheet and positive corporate developments, notably the $25M milestone tied to GSK’s NDA resubmission and the closure of the SEC investigation.

Positive Factors

Strategic Partnerships

The partnership with GSK enhances Spero's market reach and resource access, potentially leading to significant milestone payments and increased commercialization success.

Leadership Change

The new CEO, Esther Rajavelu, is expected to strengthen strategic initiatives and partnerships, potentially improving operational efficiency and business focus.

Tebipenem HBr Program

The Phase 3 PIVOT-PO trial for tebipenem HBr could offer a novel oral treatment for cUTI, potentially transforming treatment paradigms and boosting long-term growth.

Negative Factors

Revenue Decline

Significant revenue decline indicates challenges in maintaining financial stability and growth, impacting the company's ability to fund R&D and operations.

SPR720 Trial Setback

The failure of the SPR720 trial raises concerns about the viability of the pipeline, potentially affecting future revenue streams and market confidence.

Increased Financial Losses

Rising losses highlight financial strain and operational inefficiencies, necessitating strategic adjustments to improve profitability and cash flow management.

Spero Therapeutics Business Overview & Revenue Model

Company Description

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Spero Therapeutics makes money primarily through the development and commercialization of its proprietary antibiotics. Revenues are generated through partnerships, collaborations, and licensing agreements with other pharmaceutical companies and organizations, which provide funding for the development of its drug candidates. These partnerships often involve milestone payments, royalties, and shared profits from successfully developed products. Additionally, the company may receive grants and research funding from government and non-profit entities to support its research and development efforts. Key factors contributing to Spero's earnings include the successful progression of its drug candidates through clinical trials and eventual regulatory approval and commercialization.

Spero Therapeutics Financial Statement Overview

Summary

Income statement and cash flow are weak (declining TTM revenue, deeply negative net income, and ongoing cash burn), which pressures sustainability. The main offset is a relatively low-debt balance sheet that provides some financial flexibility despite falling equity and negative returns.

Income Statement

TTM (Trailing-Twelve-Months) results show a sharp deterioration versus prior profitable periods: revenue declined ~22.6% and profitability is deeply negative (net loss of ~$43.8M with negative margins). While 2023 showed strong revenue and positive earnings, the business reverted to heavy losses in 2024 and remained loss-making in TTM, highlighting high earnings volatility and weak current operating leverage.

Balance Sheet

Leverage is low with modest debt (~$3.35M TTM) and a conservative debt level versus equity (debt-to-equity ~0.13 TTM), which is a clear balance-sheet strength. However, equity has fallen meaningfully from 2023 to TTM, and returns on equity are strongly negative in TTM, signaling ongoing value dilution risk if losses persist.

Cash Flow

Cash generation is weak: TTM operating cash flow and free cash flow are both negative (~-$27.7M), and free cash flow declined ~14.4% versus the prior period. The company is effectively funding operations through non-operating sources rather than business cash generation, increasing dependence on financing and raising runway/financing-risk sensitivity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	35.77M	47.98M	103.78M	48.58M	3.07M	9.33M
Gross Profit	-72.47M	-48.78M	52.34M	48.58M	3.07M	-57.67M
EBITDA	-45.15M	-72.48M	27.15M	-42.94M	-87.17M	-78.35M
Net Income	-43.84M	-68.57M	22.81M	-46.41M	-89.76M	-78.28M
Balance Sheet
Total Assets	54.17M	110.54M	182.39M	124.80M	171.07M	153.45M
Cash, Cash Equivalents and Short-Term Investments	48.62M	52.89M	76.33M	109.11M	146.40M	126.91M
Total Debt	3.35M	4.30M	5.54M	6.65M	7.33M	7.84M
Total Liabilities	27.68M	64.42M	75.50M	48.87M	82.78M	21.41M
Stockholders Equity	26.49M	46.12M	106.89M	75.93M	88.29M	132.04M
Cash Flow
Free Cash Flow	-27.67M	-23.44M	-32.99M	-7.73M	0.00	-86.03M
Operating Cash Flow	-27.67M	-23.44M	-32.99M	-7.73M	-64.35M	-85.87M
Investing Cash Flow	0.00	0.00	0.00	33.81M	7.67M	10.47M
Financing Cash Flow	0.00	0.00	221.00K	-29.55M	84.05M	130.88M

Spero Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.29
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SPRO, the sentiment is Neutral. The current price of 2.29 is below the 20-day moving average (MA) of 2.39, below the 50-day MA of 2.35, and above the 200-day MA of 2.13, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 46.66 is Neutral, neither overbought nor oversold. The STOCH value of 30.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SPRO.

Spero Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTNM	54 Neutral	$540.64M	-6.56	-30.40%	―	―	-100.71%
CNTB	53 Neutral	$130.26M	-8.23	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MIST	49 Neutral	$159.27M	―	-260.65%	―	―	3.70%
KRRO	49 Neutral	$115.46M	-1.30	-63.46%	―	―	21.61%
SPRO	48 Neutral	$129.02M	―	-95.29%	―	-67.38%	-1076.54%
TNYA	43 Neutral	$182.32M	-1.07	-96.44%	―	―	46.68%

Spero Therapeutics Corporate Events

Spero Therapeutics Co-Founder Resigns From Board Roles

On January 30, 2026, Spero Therapeutics announced that co‑founder Ankit Mahadevia, MD resigned from its Board of Directors, its Development Committee, and all officer and director roles at its subsidiaries, citing other professional commitments and not any disagreement over the company’s operations, policies, or practices; the company expressed gratitude for his service since inception and indicated that it plans to retain him in a consulting capacity to continue supporting management. Earlier, on January 20, 2026, Spero received notice from the U.S. Securities and Exchange Commission that the regulator had concluded its previously disclosed investigation and, based on information available as of that date, did not intend to recommend an enforcement action, a development that removes a significant regulatory overhang for the company and may improve visibility and confidence for investors and other stakeholders.

The most recent analyst rating on (SPRO) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Spero Therapeutics stock, see the SPRO Stock Forecast page.

GSK Resubmits NDA, Triggering Milestone for Spero Therapeutics

On December 19, 2025, Spero Therapeutics reported that its partner GlaxoSmithKline resubmitted a New Drug Application to the U.S. Food and Drug Administration for tebipenem HBr, an oral carbapenem antibiotic candidate for the treatment of complicated urinary tract infections, including pyelonephritis. The resubmission activates a $25 million milestone payment to Spero under its license agreement with GSK, strengthening the company’s near-term cash position and underscoring the strategic importance of tebipenem HBr within its pipeline and its broader positioning in the anti-infectives market, while the program’s ultimate commercial and regulatory outcomes remain subject to significant clinical, regulatory, and execution risks.

The most recent analyst rating on (SPRO) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Spero Therapeutics stock, see the SPRO Stock Forecast page.

Spero Therapeutics Reports Q3 2025 Financial Results

On November 13, 2025, Spero Therapeutics announced its third-quarter financial results and provided a business update. The company highlighted the Phase 3 PIVOT-PO trial results for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections, which demonstrated non-inferiority to intravenous treatments. Spero’s partner, GSK, plans to submit these results to the FDA in the fourth quarter of 2025. The company reported a net loss of $7.4 million for the third quarter of 2025, a decrease from the previous year, and expects its current cash reserves to fund operations into 2028.

The most recent analyst rating on (SPRO) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Spero Therapeutics stock, see the SPRO Stock Forecast page.